Medicare Part D formularies sort covered drugs into cost-sharing tiers, and the specialty tier sits at the top of that structure as the most expensive tier a beneficiary can face. CMS defines a specialty tier drug using an annual ingredient-cost threshold: a drug qualifies once its cost for a 30-day equivalent supply exceeds $950 in 2026, unchanged from the 2024 and 2025 threshold and set to rise to $1,080 in 2027 under CMS's published methodology. Plans are not required to have a specialty tier, but nearly every Part D plan in 2026 designates one, because specialty drugs, mostly biologics, oncology therapies, and treatments for rare diseases, account for a disproportionate share of total Part D spending relative to how many beneficiaries use them. Unlike the four tiers below it (preferred generic, generic, preferred brand, and non-preferred drug), which typically carry flat-dollar copays, the specialty tier almost always uses coinsurance, a percentage of the drug's price, because a flat copay large enough to offset a $10,000-a-month drug would be unworkable for both plans and patients. Some plans maintain two specialty tiers, a lower-cost and a higher-cost specialty tier, which changes how tiering exceptions can work, covered later on this page.
Coinsurance on the 2026 specialty tier ranges from 25% to 33% of the drug's negotiated price, according to KFF's annual analysis of Part D benefit design. The median rate is 25% among standalone Prescription Drug Plans and 28% among Medicare Advantage Prescription Drug Plans, and federal rule allows a plan to set specialty tier coinsurance above 25% only if the plan waives some or all of the standard $615 deductible for 2026, which most Medicare Advantage plans with drug coverage do. Applied to real numbers, a drug at the $950 specialty threshold costs $237.50 at 25% coinsurance and $313.50 at 33% coinsurance for a single 30-day fill, before any deductible is applied. Applied to a much more expensive specialty drug, such as a biologic listed at $13,836 a month, the same percentages produce $3,459 at 25% and $4,566 at 33% for one fill, an amount that alone comes close to exhausting the entire $2,100 annual Part D out-of-pocket cap in 2026. This is why specialty tier drugs, more than any other tier, drive beneficiaries into the Part D catastrophic phase within the first one or two fills of the calendar year.
Federal rule 42 CFR 423.578 gives Part D plans the option to exclude specialty tier drugs from the standard tiering exception process entirely, and effective January 1, 2022, most plans exercise that option, meaning a beneficiary generally cannot ask a plan to move a specialty-tier drug to a cheaper, non-specialty tier the way they could for a non-preferred brand drug. The one carve-out: if a plan maintains two specialty tiers, a lower-cost and a higher-cost tier, it must allow exception requests to move a drug from the higher specialty tier down to the lower one. Two developments can lower a beneficiary's specialty tier exposure without an exception request. First, biosimilar and generic competition can push a drug's 30-day ingredient cost below the $950 threshold, moving it off the specialty tier entirely; Humira (adalimumab) now has more than ten FDA-approved biosimilars, though the lowest-priced options remain above $1,015 a month, so most still sit on the specialty tier despite the competition. Second, for the ten drugs with Inflation Reduction Act Maximum Fair Prices effective January 1, 2026, including Stelara and Enbrel, coinsurance is calculated against the lower negotiated price rather than the pre-negotiation list price, which sharply cuts the dollar amount even though the coinsurance percentage stays the same.
What Specialty Tier Coinsurance 2026 Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same specialty tier coinsurance 2026 can cost many times more at a hospital than at your local pharmacy:
2026 Specialty Tier Coinsurance 2026 Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty tier drug at 25% coinsurance (2026, PDP median) | $237.50 to $3,459 per 30-day fill | Range models a $950 (threshold) to $13,836 (list price) specialty drug; applies before you reach the $2,100 annual OOP cap |
| Specialty tier drug at 33% coinsurance (2026, highest published rate) | $313.50 to $4,566 per 30-day fill | Plans may set coinsurance above 25% only if they waive some or all of the $615 (2026) standard deductible |
| IRA-negotiated specialty drug (Stelara Maximum Fair Price, 2026) | $1,174 to $1,550 per 30-day fill (25% to 33% of $4,695) | Coinsurance is based on the negotiated $4,695 Maximum Fair Price, not the pre-negotiation $13,836 list price, effective January 1, 2026 |
| Annual Part D deductible (2026 maximum) | Up to $615/year | You pay 100% of drug cost, including specialty tier drugs, until the deductible is met, unless your plan waives it |
| Part D annual OOP cap (catastrophic coverage) | $2,100/year then $0 | One or two specialty tier fills early in the year can nearly reach this cap; after $2,100 the plan covers 100% for the rest of the calendar year |
The 2026 specialty tier threshold ($950), coinsurance range (25% to 33%), and the $2,100 OOP cap are set by CMS in the Specialty Tier Cost Threshold Methodology and the Final CY 2026 Part D Redesign Program Instructions. Actual dollar amounts depend on the specific drug's negotiated price and your plan's specialty tier design.
Source: CMS Specialty Tier Cost Threshold Methodology (CY 2026); CMS Final CY 2026 Part D Redesign Program Instructions; KFF Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026; CMS Medicare Drug Price Negotiation Program Negotiated Prices for 2026
Why Hospitals Charge So Much
Percentage-based coinsurance exists on the specialty tier because a flat-dollar copay large enough to meaningfully offset the cost of a $10,000-to-$14,000-a-month biologic would defeat the purpose of insurance, either bankrupting the plan's cost-sharing design or making the copay itself unaffordable for most beneficiaries. CMS's specialty tier methodology ties cost-sharing to a percentage of the drug's actual price specifically so that plans share in the financial risk of high-cost drugs proportionally, rather than absorbing a fixed loss on every fill. The tradeoff is that beneficiaries face open-ended dollar exposure per fill instead of a predictable copay, which is the central complaint specialty tier patients raise every plan year.
The 2026 Part D benefit redesign changes how that exposure plays out across the calendar year. Before the Inflation Reduction Act's redesign took effect in 2025, a beneficiary in the old coverage gap could face 25% coinsurance with no hard annual ceiling until crossing a much higher total drug-spending threshold. In 2026, the $2,100 annual out-of-pocket cap means a single specialty tier fill in January, even one costing $3,000 or $4,000 in coinsurance, effectively caps that beneficiary's out-of-pocket drug spending for the rest of the year once the cap is reached. The practical result: most specialty tier patients now pay their entire annual drug cost exposure in one or two large payments early in the year, rather than a smaller amount spread across twelve months.
Drug manufacturers now absorb part of this cost too. Under the Manufacturer Discount Program that replaced the old Coverage Gap Discount Program in 2025, manufacturers provide a 10% discount on applicable brand drugs during the initial coverage phase and a 20% discount during the catastrophic phase, with Medicare and the plan covering the remainder. That cost-sharing structure gives manufacturers a direct financial stake in keeping list prices in check, and it is part of why manufacturers with drugs selected for Inflation Reduction Act negotiation, such as Stelara and Enbrel, have accepted Maximum Fair Prices that cut specialty tier coinsurance dollar amounts substantially starting January 1, 2026.
Patient Assistance Programs
Specialty tier drugs are disproportionately biologics, oncology therapies, and rare-disease treatments, exactly the categories where manufacturers operate the most established patient assistance programs (PAPs). Bristol Myers Squibb, Janssen, Novartis, AbbVie, Amgen, and most other manufacturers with specialty-priced drugs run income-based PAPs that provide free or steeply discounted drug supply, separate from the plan's specialty tier coinsurance entirely. Because most specialty tier drugs are also protected-class or high-severity medications, beneficiaries who cannot afford the 25% to 33% coinsurance should apply directly to the manufacturer rather than delaying treatment.
Patient assistance programs for Specialty Tier Coinsurance 2026| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Manufacturer Patient Assistance Program (PAP) | Free or low-cost specialty drug supply for income-eligible patients, typically at or below 300% to 400% of the Federal Poverty Level; separate from Part D specialty tier coinsurance entirely | needymeds.org |
| Medicare Extra Help (Low Income Subsidy) | Caps specialty tier cost-sharing at $1.60 to $4.90 per drug (full subsidy, at or below poverty level) or $5.10 to $12.65 per drug (full subsidy, above poverty level), replacing the 25% to 33% coinsurance rate | ssa.gov/extrahelp |
| State Pharmaceutical Assistance Programs (SPAPs) | Available in roughly two dozen states; may supplement Part D specialty tier coinsurance for eligible beneficiaries | medicare.gov/plan-compare |
| NeedyMeds Drug Assistance Program Search | Free directory connecting patients to manufacturer PAPs and copay assistance for specific specialty drugs by name | needymeds.org |
Manufacturer copay cards and savings coupons cannot legally be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). If you have Medicare and your specialty tier drug's coinsurance is unaffordable, apply directly to the manufacturer's income-based patient assistance program, not a commercial copay card, and separately check Medicare Extra Help eligibility, since the two programs can be used together.
Source: NeedyMeds.org, SSA Extra Help program, Medicare.gov Plan Finder, CMS Anti-Kickback Statute guidance
Medicare Part D
Specialty tier placement is set at the individual plan level, not by CMS drug-by-drug, which means the same drug can sit on the specialty tier in one Part D plan and a lower tier in another, depending on each plan's formulary design and rebate negotiations. CMS only sets the $950 (2026) minimum ingredient-cost threshold a drug must cross to be eligible for specialty tier placement; whether a specific plan actually places an eligible drug on its specialty tier, and what coinsurance percentage it charges within the 25% to 33% range, varies by plan. Specialty tier drugs frequently also carry a separate prior authorization requirement, a clinical review a plan performs before it will cover the drug at all, which is independent of tiering and cannot be resolved by a tiering exception. Beneficiaries should check a plan's published formulary through the Medicare Plan Finder at medicare.gov/plan-compare before enrolling if they take a high-cost specialty drug, since switching plans is generally limited to the Annual Enrollment Period, October 15 through December 7, effective the following January 1.
Six protected drug classes, immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics, must be covered by every Part D plan regardless of formulary tier, and many protected-class drugs, especially antineoplastics (cancer drugs) and immunosuppressants, are specialty-tier priced. Protected-class status guarantees coverage; it does not guarantee a lower coinsurance rate. A cancer patient on a protected-class antineoplastic that happens to cost $8,000 a month will still face 25% to 33% coinsurance on the specialty tier unless they qualify for Extra Help or a manufacturer PAP, even though the plan cannot refuse to cover the drug or apply step therapy to it.
Extra Help (the Low Income Subsidy) is the most direct lever a specialty tier patient has within Medicare itself. In 2026, full-subsidy beneficiaries with income at or below the poverty level pay a flat $1.60 for a generic and $4.90 for a specialty or brand drug, and full-subsidy beneficiaries above the poverty level pay $5.10 and $12.65, regardless of whether the plan's underlying specialty tier coinsurance is 25% or 33%. Because Extra Help replaces percentage coinsurance with a flat dollar cap, it is disproportionately valuable for beneficiaries taking specialty tier drugs, where the gap between the plan's stated coinsurance percentage and the Extra Help copay can be worth thousands of dollars a year.
Common Specialty Tier Coinsurance 2026 Billing Errors
Specialty tier billing involves more moving parts than a standard copay, which creates several common errors. If your specialty tier charge does not match your plan's Evidence of Coverage or Explanation of Benefits, dispute it with your plan:
- Charged the pre-negotiation list price coinsurance on an IRA-negotiated drug (Stelara, Enbrel, Imbruvica) instead of coinsurance based on the lower 2026 Maximum Fair Price
- Full Extra Help enrollee charged the plan's standard 25% to 33% specialty tier coinsurance instead of the correct $1.60 to $12.65 flat copay cap
- Continued coinsurance charged after the beneficiary already reached the $2,100 annual Part D out-of-pocket cap for the calendar year
- Drug placed on the specialty tier despite its 30-day ingredient cost falling below the $950 (2026) threshold after a mid-year price change or biosimilar entry
- Tiering exception request denied without a written notice citing 42 CFR 423.578, when the plan maintains two specialty tiers and the request was to move between them
- Specialty pharmacy billing the drug outside the plan's required specialty pharmacy network at a higher cash rate instead of the required in-network rate
Frequently Asked Questions
Is there a generic or biosimilar for specialty tier drugs?
It depends on the specific drug. Specialty tier status is based on price, not brand status, so any drug, brand, generic, or biosimilar, with a 30-day ingredient cost above $950 in 2026 qualifies. Biosimilar competition can eventually push a drug below that threshold. Humira (adalimumab) now has more than ten FDA-approved biosimilars as of 2026, but the lowest-priced options still run above $1,015 a month, so most remain on the specialty tier despite competition. Ask your prescriber whether a lower-cost generic or biosimilar exists for your specific specialty drug.
How do I apply for a manufacturer patient assistance program for a specialty tier drug?
Search for your specific drug's manufacturer PAP by name on needymeds.org or call 1-800-503-6897. Gather proof of income, proof of US residency, your Part D plan's specialty tier cost documentation, and a valid prescription. Submit the application by fax, mail, or online portal; most manufacturers process requests within 7 to 14 business days. If approved, the drug typically ships free directly to you or your prescriber, separate from your Part D specialty tier billing.
Can I use a manufacturer copay card with Medicare for a specialty tier drug?
No. Federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars any manufacturer coupon, copay card, or savings coupon from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries, regardless of the drug's tier. If your specialty tier coinsurance is unaffordable, apply to the manufacturer's income-based patient assistance program instead, which is legal for Medicare patients and separate from a commercial copay card.
What if my insurance denies coverage or places my drug on the specialty tier?
Request a written Coverage Determination within 72 hours (24 hours expedited), then file a formal appeal (redetermination) within 60 days if denied. If the drug's 30-day cost is actually below the $950 (2026) specialty threshold, or an IRA-negotiated Maximum Fair Price should apply, include that documentation. Note that most plans exclude specialty tier drugs from standard tiering exceptions under 42 CFR 423.578, so a tiering exception typically only works if your plan has two specialty tiers and you are asking to move to the lower one.
Does the IRA negotiated price apply to specialty tier drugs like Stelara and Enbrel?
Yes, for the ten drugs with Inflation Reduction Act Maximum Fair Prices effective January 1, 2026, including Stelara ($4,695, down from $13,836) and Enbrel ($2,355, down from $7,106). Specialty tier coinsurance is calculated against the lower negotiated price, not the pre-negotiation list price, which sharply cuts the dollar coinsurance even though the plan's coinsurance percentage (25% to 33%) stays the same. Drugs not selected for negotiation still use the full list price as the coinsurance base.
What does 25% to 33% specialty tier coinsurance actually cost per month in 2026?
On a drug at the $950 (2026) specialty threshold, 25% coinsurance costs $237.50 and 33% costs $313.50 for one 30-day fill. On a more expensive biologic listed at $13,836 a month, the same percentages produce $3,459 and $4,566 for a single fill, an amount that alone comes close to the entire $2,100 annual Part D out-of-pocket cap. Most specialty tier patients reach the $2,100 cap within their first one or two fills of the calendar year.
Do I qualify for Extra Help to lower my specialty tier drug cost?
You may qualify for Medicare Extra Help (Low Income Subsidy) in 2026 if your income is at or below roughly 150% of the Federal Poverty Level, about $23,475 a year for a single person, and your resources are below $18,090 (individual). Full-subsidy beneficiaries at or below the poverty level pay $1.60 for a generic and $4.90 for a specialty drug; those above the poverty level pay $5.10 and $12.65, regardless of the plan's stated 25% to 33% specialty tier coinsurance. Apply through Social Security at ssa.gov/extrahelp or by calling 1-800-772-1213.
Can I get my drug moved off the specialty tier through a tiering exception?
Usually not. Federal rule 42 CFR 423.578 allows Part D plans to exclude specialty tier drugs from the standard tiering exception process entirely, and most plans do exactly that as of January 1, 2022. The only guaranteed exception applies if your plan maintains two specialty tiers, a lower-cost and higher-cost tier, in which case it must let you request moving a drug from the higher tier down to the lower one. If your plan has only one specialty tier, your realistic options are a formulary exception based on medical necessity, Medicare Extra Help, or a manufacturer patient assistance program.
